Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Ethyl Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.42 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.36 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.36 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL2336202 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10TSHRMEN1 | |
| Ethyl Acetate SCHEMBL390477 | 1.00 | — | — | |
| Ethyl Acetate SCHEMBL5862364 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10TSHRMEN1 | |
| Ethyl Acetate SCHEMBL10517706 | 0.97 | ALDH1A1 (0.70) | ALDH1A1LMNAHSD17B10TSHRMEN1 | |
| Ethyl Acetate SCHEMBL4048106 | 0.97 | ALDH1A1 (0.70) | ALDH1A1LMNAHSD17B10TSHRMEN1 | |
| Ethyl Acetate SCHEMBL2010629 | 0.97 | ALDH1A1 (0.70) | ALDH1A1LMNAHSD17B10TSHRMEN1 | |
| Ethyl Acetate SCHEMBL5502461 | 0.97 | ALDH1A1 (0.70) | ALDH1A1LMNAHSD17B10TSHRMEN1 | |
| Ethyl Acetate SCHEMBL9131985 | 0.95 | ALDH1A1 (0.67) | ALDH1A1LMNAHSD17B10TSHRMEN1 | |
| Ethyl Acetate SCHEMBL7382473 | 0.95 | ALDH1A1 (0.67) | ALDH1A1LMNAHSD17B10TSHRMEN1 | |
| Ethyl Acetate SCHEMBL29038936 | 0.95 | ALDH1A1 (0.67) | ALDH1A1LMNAHSD17B10TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114280201-B | Efficient separation method of polyphenol components in dandelion | 山东省千佛山医院 | 2023-06-13 | — | — | CN | claimed |
| CN-114280201-A | Efficient separation method for polyphenol components in dandelion | 山东省千佛山医院 | 2022-04-05 | — | — | CN | claimed |
| US-20180057481-A1 | SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE | TOBIRA THERAPEUTICS, INC. | 2018-03-01 | — | — | US | claimed |
| CN-100486970-C | Preparation method of racemic homocitric acid lactone | UNIV XIAMEN (CN) | 2009-05-13 | — | — | CN | claimed |
| CN-1948299-A | Preparation method of racemic homocitric acid lactone | XIAMEN UIV (CN) | 2007-04-18 | — | — | CN | claimed |
| CN-114280201-B | Efficient separation method of polyphenol components in dandelion | 山东省千佛山医院 | 2023-06-13 | — | — | CN | disclosed |
| CN-114280201-B | Efficient separation method of polyphenol components in dandelion | 山东省千佛山医院 | 2023-06-13 | — | — | CN | disclosed |
| US-20220204481-A1 | PROTEIN AND/OR PEPTIDE MODIFICATION MOLECULE | OSAKA UNIVERSITY (JP) | 2022-06-30 | — | — | US | disclosed |
| CN-114280201-A | Efficient separation method for polyphenol components in dandelion | 山东省千佛山医院 | 2022-04-05 | — | — | CN | disclosed |
| CN-114280201-A | Efficient separation method for polyphenol components in dandelion | 山东省千佛山医院 | 2022-04-05 | — | — | CN | disclosed |
| EP-3932912-A1 | PROTEIN AND/OR PEPTIDE MODIFICATION MOLECULE | Osaka University (JP) | 2022-01-05 | — | — | EP | disclosed |
| CN-113185406-A | Efficient preparation method of phenolic acid active ingredients in salvia yunnanensis | 山东省分析测试中心 | 2021-07-30 | — | — | CN | disclosed |
| CN-1948299-A | Preparation method of racemic homocitric acid lactone | XIAMEN UIV (CN) | 2007-04-18 | — | — | CN | disclosed |
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-07 | — | — | US | disclosed |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2005-10-06 | — | — | US | disclosed |
| US-4013707-A | PROSTAGLANDINS, ANTISPASMODIC, ANTIASTHMA, HYPOTENSIVE | THE UPJOHN COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-4013693-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-3969464-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1976-07-13 | — | — | US | disclosed |
| US-3952048-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-04-20 | — | — | US | disclosed |
| US-3948970-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199826-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | MEN1 1818/4885CHRM2 213/4885CHRM4 1067/4885 |
| US-20220204481-A1 | PROTEIN AND/OR PEPTIDE MODIFICATION MOLECULE | PTMS, DNPEP, NPPA | MEN1 496/4885CHRM2 4280/4885CHRM4 4289/4885 |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | MMP13, MMP11, MMP1 | MEN1 1233/4885CHRM2 138/4885CHRM4 758/4885 |
| US-20180057481-A1 | SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE | TYMP, MTAP, TYMS | MEN1 915/4885CHRM2 4380/4885CHRM4 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.